. . . . . . . "[Identifying the biologically active component (s) responsible for the neuropsychological benefit in APOE ?4-positive AD patients could enable the development of a compound with greater potency that would qualify for FDA (US Food and Drug Administration) registration.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:10:37+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .